Seroprevalence of hepatitis B among the general population in Shandong Province, Eastern China, an update 30 years after the implementation of the neonatal vaccination program.

Seroprevalence of hepatitis B among the general population in Shandong Province, Eastern China, an update 30 years after the implementation of the neonatal vaccination program.

Publication date: Dec 18, 2024

In 1992, Hepatitis B vaccine was first recommended for routine neonatal immunization in China. This study aimed to estimate the prevalence of hepatitis B virus (HBV) infection in Shandong Province, eastern China (updating our previous study in 2014), and to help guide the efforts of hepatitis B elimination. We determined prevalence of HBV infection from the remaining serum samples collected through a population-based survey, which was originally intended for a seroepidemiological survey of anti-SARS-CoV-2 antibodies conducted in 2023. The samples (nā€‰=ā€‰5000) were obtained from individuals all-aged over 1 year residing in ten counties of Shandong Province. The chemiluminescence microparticle immunoassay was used to detect serological markers of HBV. In total, 4999 samples were eligible for the test of hepatitis B. The overall prevalence of HBsAg, anti-HBs, and anti-HBc in the 2023 survey was 2. 25% (95%CI:1. 64-2. 87), 46. 21% (95%CI:44. 05-48. 38), and 25. 17% (95%CI:23. 46-26. 88), respectively. The HBsAg prevalence has dropped to 0. 28% among individuals younger than 30 years, particularly with less than 0. 1% among children aged 1-14 (considerably below the 8% prevalence recorded in 1992). The peak prevalence of HBsAg was observed in individuals aged 40-49 years (5. 63%), followed by those aged 30-39 (3. 11%). The Shandong Province has achieved substantial success in controlling HBV infection among the younger generation through the newborn routine vaccination program. To accelerate progress towards the goal of eliminating hepatitis B in the province, additional strategies should also be adopted in parallel, including increasing diagnostic coverage, expanding antiviral treatment, and enhancing hepatitis B vaccine coverage for HBV-susceptible adults.

Open Access PDF

Concepts Keywords
China Adolescent
Counties Adult
Hepatitis Aged
Neonatal Child
Child, Preschool
China
Female
HBV elimination
Hepatitis B
Hepatitis B
Hepatitis B Antibodies
Hepatitis B Antibodies
Hepatitis B vaccine
Hepatitis B Vaccines
Hepatitis B Vaccines
Hepatitis B virus
Humans
Immunization Programs
Infant
Infant, Newborn
Male
Middle Aged
Prevalence
Prevalence
Sero-epidemiology
Seroepidemiologic Studies
Vaccination
Young Adult

Semantics

Type Source Name
disease MESH hepatitis B
pathway KEGG Hepatitis B
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
disease MESH infection
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Spinosad
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH Hepatitis
drug DRUGBANK Polyethylene glycol
disease IDO immunodeficiency
disease MESH syphilis
drug DRUGBANK Hepatitis B Immune Globulin
drug DRUGBANK Ademetionine
disease IDO assay
disease IDO reagent
drug DRUGBANK Etoperidone
disease IDO production
disease MESH chronic renal failure
drug DRUGBANK Tretamine
disease IDO country
disease MESH complications
disease MESH cirrhosis
disease MESH liver failure
disease MESH carcinoma
disease IDO history
drug DRUGBANK Troleandomycin
disease IDO blood
disease MESH virus infection
disease MESH mother to child transmission
disease MESH Chronic Hepatitis
disease MESH STIs
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Morbidity
disease MESH liver disease

Original Article

(Visited 1 times, 1 visits today)